Risk of hospitalisation and death related to baclofen for alcohol use disorders: Comparison with nalmefene, acamprosate, and naltrexone in a cohort study of 165 334 patients between 2009 and 2015 in France

PURPOSE: Baclofen is widely used off‐label for alcohol use disorders (AUD) in France, despite its uncertain efficacy and safety, particularly at high doses. This study was designed to evaluate the safety of this off‐label use compared to the main approved drugs for AUD (acamprosate, naltrexone, nalm...

Descripción completa

Detalles Bibliográficos
Autores principales: Chaignot, Christophe, Zureik, Mahmoud, Rey, Grégoire, Dray‐Spira, Rosemary, Coste, Joël, Weill, Alain
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Original Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6282718/
https://www.ncbi.nlm.nih.gov/pubmed/30251424
http://dx.doi.org/10.1002/pds.4635

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6282718/
https://www.ncbi.nlm.nih.gov/pubmed/30251424
http://dx.doi.org/10.1002/pds.4635

Ejemplares similares